TAKHZYRO (lanadelumab) is a prescription medication used for the prevention of attacks in individuals with hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, intestinal tract, and airways. TAKHZYRO is a monoclonal antibody that works by inhibiting the activity of plasma kallikrein, a protein that plays a key role in the inflammatory process leading to swelling attacks in HAE patients. Administered through subcutaneous injection, TAKHZYRO has been shown to significantly reduce the frequency of HAE attacks, improving the quality of life for those living with this condition. It is typically prescribed for patients 12 years of age and older, although dosing and use can vary based on individual patient needs and the specifics of their condition.